Langlois Sophia J. 4

What Happened

• Sophia J. Langlois, a director of Keenova Therapeutics plc, had restricted stock units (RSUs) settle on June 2, 2026. The filing reports 2,685 RSUs converted into ordinary shares (one share per RSU). Of the resulting shares, 1,289 were withheld to satisfy tax withholding obligations, and 2,197 RSUs were forfeited/disposed to the issuer pursuant to an agreement with the company. No cash purchase price or market value is reported for these transactions.

Key Details

• Transaction date: June 2, 2026; Form 4 filed June 4, 2026 (appears timely).
• Reported events/codes: M (exercise/conversion of derivative — RSU settlement) 2,685 shares; F (tax withholding) 1,289 shares; D (disposition to issuer) 2,197 shares. One entry shows the derivative conversion with $0.00 price.
• Shares owned after the transactions: not specified in the provided filing.
• Notable footnotes:
  • F1: Each settled RSU converted to one ordinary share.
  • F2: Tax-withheld share count was based on a percentage; no market value used because Keenova shares are not listed or quoted.
  • F3/F5: The 2,197 RSUs were forfeited under an agreement in exchange for a payment from the issuer to help the reporting person satisfy certain tax obligations.
  • F4: The RSUs were granted Aug 14, 2025 and vest on the earlier of the first anniversary of the grant or the issuer’s next annual general meeting.
• Filing also serves as notice to the issuer under Part V of the Companies Act 2014 (per the filing’s remarks).

Context

• These were RSU settlements and administrative dispositions (tax withholding and a negotiated forfeiture/payment), not open-market sales or purchases; such transactions often reflect routine vesting and tax handling rather than a buy/sell signal.
• Because the company’s shares are not listed/quoted, no dollar values or market prices were reported in the filing.